Peptide therapy has moved from obscure corners of performance medicine into mainstream wellness conversations with remarkable speed, and without a corresponding acceleration in the quality of clinical evidence. Patients arrive having already purchased peptides online, having researched dosing protocols on forums, and wanting physician oversight for something they have already decided to do. That is not a conversation I discourage. But it requires an honest accounting of what we actually know.
Peptides are short chains of amino acids, smaller than proteins, larger than individual amino acids, that act as biological signalling molecules. Many are naturally occurring sequences found in the body; synthetic versions either mimic these endogenous peptides or are designed to modulate specific receptor pathways. The therapeutic premise is sound. The challenge is evidence quality and regulatory status.
Several peptides discussed here, including BPC-157, are currently classified as research chemicals in the United States and are not FDA-approved for human use. This article presents the clinical literature as it exists. Any use should be under physician supervision with full understanding of the regulatory context.
BPC-157: The Most Discussed, the Most Misrepresented
Body Protection Compound-157 is a synthetic peptide derived from a protein found in gastric juice. The animal literature on BPC-157 is genuinely compelling: accelerated tendon and ligament healing, gastroprotective effects, angiogenesis promotion, and neuroprotective properties have all been demonstrated in rodent models. The problem is that virtually all of this evidence is preclinical. There are no published randomised controlled trials in humans for the applications most commonly cited.
That does not mean BPC-157 does not work in humans. It means we do not yet have rigorous human evidence. The rodent-to-human translation in peptide research has historically been unreliable in both directions. Patients using BPC-157 for tendon injuries or gut healing are acting on promising but unvalidated data, and should understand that distinction.
TB-500: Tissue Repair and the Thymosin Question
TB-500 is a synthetic fragment of Thymosin Beta-4, an endogenous peptide involved in cell migration, wound healing, and inflammation modulation. The evidence base is similar to BPC-157: strong animal data, particularly for cardiac and musculoskeletal repair, with limited human clinical trials. A small number of human studies have examined topical application for wound healing with positive results; systemic injectable use for athletic recovery remains in the realm of anecdotal reporting and theoretical extrapolation from the preclinical literature.
The combination of BPC-157 and TB-500, marketed as a "healing stack", is popular in performance communities for injury recovery. The synergy hypothesis is biologically plausible given their different but complementary mechanisms. The evidence for the combination specifically is, again, animal-model only.
Ipamorelin: The Most Clinically Grounded of the Three
Ipamorelin occupies a different evidence tier. As a growth hormone secretagogue, a compound that stimulates the pituitary to produce growth hormone rather than introducing exogenous GH directly, Ipamorelin has a more developed clinical literature and a cleaner regulatory history in the research context. It produces a selective, pulsatile GH release without significantly affecting cortisol or prolactin, which distinguishes it from older GHRP compounds.
Clinical applications include GH optimisation in adults with age-related decline, body composition support, and sleep quality improvement via GH-mediated slow-wave augmentation. It is typically combined with a GHRH analogue (most commonly CJC-1295) to produce a synergistic GH pulse. This combination has the strongest evidence base among the peptides most commonly discussed in performance medicine contexts.
Our Clinical Position
At Ultra Healthy Human, we do not reflexively endorse peptide protocols, and we do not reflexively dismiss them. Our position is to match the strength of the intervention to the strength of the evidence and the clinical picture of the individual patient.
For GH optimisation in patients with documented decline and appropriate symptom profiles, Ipamorelin-based protocols have a reasonable evidence basis and a well-understood mechanism. For BPC-157 and TB-500, we discuss the preclinical evidence honestly with patients, explain what is and is not known, and make decisions on a case-by-case basis with full informed consent. We do not manage patients who are self-administering peptides obtained from unregulated sources without establishing safety baselines.
The peptide space will develop a stronger evidence base over the next decade. In the meantime, physician oversight, honest evidence appraisal, and quality-controlled sourcing are the minimum standards for safe use.
Explore evidence-based optimisation
If you are considering peptide therapy, or already using it, physician oversight is not optional. We provide honest evidence appraisal, baseline labs, and clinical monitoring for patients exploring advanced optimisation protocols.